New ETF Book by Larry Connors - Click here to read more
The service expertise of DNA Link spans microarrays and next-generation sequencing, as well as personal genomics. DNA Link is an emerging leader in medical genetics research that is focused on establishing strong alliances with major hospitals to perform research on the genetic basis of common diseases. Included in these important studies, DNA Link has been selected by the Korean NIH as the genotyping service provider for the Korean Association Resource (KARE) project, which is the largest GWAS project in Korea for 2007, 2008, and 2009. DNA Link has also operated the DNAChip Center in collaboration with five Disease Genome Research Centers, who are being funded by the Korean Government, whose aim is to develop diagnostic markers for common diseases.
"We're pleased to add the NimbleGen Sequence Capture service to our services portfolio," said Dr. Jong E. Lee, CEO of DNA Link, Inc. "Targeted region sequencing using Sequence Capture technology could be the fine mapping study after the GWAS projects. We expect that it will accelerate the development of biomarkers related with diseases.
"Roche NimbleGen welcomes DNA Link, Inc. as our first certified service provider globally for Sequence Capture technology. We anticipate that our relationship with DNA Link, Inc. will accelerate the discovery of diagnostic markers by Korean researchers and put Roche Applied Science at the leading edge of personalized healthcare solutions through the use of NimbleGen arrays," said Dr. Gerd Maass, CEO of Roche NimbleGen, Inc.
For more information on the technology, go to www.nimblegen.com.
About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All products are sold for life science research use only. Not for use in diagnostic procedures.
454, 454 SEQUENCING, 454 LIFE SCIENCES, GS FLX TITANIUM, NIMBLEGEN, and SEQCAP are trademarks of Roche. All other brands or product names are trademarks of their respective holders.
SOURCE: Roche NimbleGen
Roche Diagnostics Dr. Burkhard Ziebolz Phone: +49 8856 604830 Email: burkhard.ziebolz@roche.com or Roche NimbleGen Kary Staples Phone: +1 608 218 7623 Email: kary.staples@roche.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
